Simon Jules Nebel
Chairman chez MARINOMED BIOTECH AG
Profil
Over the past 20 years, Simon was involved in 4 Private Equity vehicles in healthcare and renewable energy as Managing Partner at Aravis with combined assets in excess of USD 300M.
These funds invested in over 25 companies of which 19 healthcare companies; 15 healthcare companies either became public companies (SWX, ATX & NASDQ) or were acquired.
In 2016 Simon founded Viopas Venture Consulting where he is Managing Partner.
Simon has extensive experience as Board of Directors from public & private companies.
He currently holds four Board positions.
Simon holds a master and a PhD in structural biology from the Biozentrum, University of Basel as well as an MBA from the London Business School.
Postes actifs de Simon Jules Nebel
| Sociétés | Poste | Début |
|---|---|---|
| MARINOMED BIOTECH AG | Chairman | 02/06/2017 |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Private Equity Investor | 01/01/2002 |
Quadia SA
 Quadia SA Investment ManagersFinance Quadia SA (Quadia) is an independent investment firm founded in 2010. The firm is headquartered in Switzerland. | Director/Board Member | 01/03/2023 |
DyCare
 DyCare Medical SpecialtiesHealth Technology DyCare is a Spanish company that specializes in digital rehabilitation. The company is based in Barcelona, Spain. The company creates ultra-personalized exercises and monitor patients in a simple and effective way. The company's technology allows patients to perform therapeutic exercises using only their mobile phone or tablet camera, assisted by artificial intelligence. The company was founded by Silvia Raga and Ricardo Jauregui, who have been the CEOs since incorporation. | Director/Board Member | 01/02/2022 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Founder | 01/09/2016 |
Anciens postes connus de Simon Jules Nebel
| Sociétés | Poste | Fin |
|---|---|---|
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Director/Board Member | 30/08/2023 |
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Director/Board Member | 30/06/2023 |
| Digital Dr. House AG | Director/Board Member | 31/03/2023 |
Viopas Partners AG
 Viopas Partners AG Investment ManagersFinance Zoeyplus AG(Zoeyplus) is a Private Equity subsidiary of Viopas Venture Consulting GmbH founded in 2018 by Simon Jules Nebel, Nathalie Flury and Michael Schröter. The firm is headquartered in Zurich, Switzerland. | Founder | 31/12/2020 |
| ░░░░░░ ░░░░░░░ ░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Simon Jules Nebel
| University of Basel | Doctorate Degree |
| London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MARINOMED BIOTECH AG | Health Technology |
| NORTHERN DATA AG | Technology Services |
| Entreprise privées | 15 |
|---|---|
Borean Pharma ApS
 Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Borean Pharma ApS provides biopharmaceuticals drugs and protein engineering services. Its two main components of technology platform are CTLD library technology and trimerisation technology. The company was founded by Hans Christian Thøgersen and Michael Etzerodt in 1997 and is located in Aarhus, Denmark. | Health Technology |
Aravis AG
Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Finance |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Health Technology |
Aravis Venture II LP
 Aravis Venture II LP Investment ManagersFinance Aravis Venture II LP invests in biotechnological start-ups with growth potential. | Finance |
ImVisioN Therapeutics AG
 ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Commercial Services |
leading swiss renewables AG
 leading swiss renewables AG Financial ConglomeratesFinance leading swiss renewables AG owns and operates renewable energy development projects. It specializes in the production and management of renewable energy sources, with focus on the development of energy production plants and facilities. The company was founded on October 1, 2010 and is headquartered in Muenchenstein, Switzerland. | Finance |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
Quadia SA
Quadia SA Investment ManagersFinance Quadia SA (Quadia) is an independent investment firm founded in 2010. The firm is headquartered in Switzerland. | Finance |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Viopas Partners AG
Viopas Partners AG Investment ManagersFinance Zoeyplus AG(Zoeyplus) is a Private Equity subsidiary of Viopas Venture Consulting GmbH founded in 2018 by Simon Jules Nebel, Nathalie Flury and Michael Schröter. The firm is headquartered in Zurich, Switzerland. | Finance |
DyCare
DyCare Medical SpecialtiesHealth Technology DyCare is a Spanish company that specializes in digital rehabilitation. The company is based in Barcelona, Spain. The company creates ultra-personalized exercises and monitor patients in a simple and effective way. The company's technology allows patients to perform therapeutic exercises using only their mobile phone or tablet camera, assisted by artificial intelligence. The company was founded by Silvia Raga and Ricardo Jauregui, who have been the CEOs since incorporation. | Health Technology |
| Digital Dr. House AG | |
| MerLion Pharmaceuticals SA |
